Ecron Acunova (EA), a CRO with presence in Europe and Asia, announced a joint venture with Jamjuree Innovations Co. Ltd., (JJI) Thailand. JJI is a 100% subsidiary of Chulalongkorn University Intellectual Property Foundation and enjoys strong ties with the University’s Faculty of Medicine, including Clinical Research Center (Chula CRC). The joint venture CRO is based in Bangkok and will conduct clinical research in key South East Asian countries under the name Ecron Acunova Company Ltd (EACL). Dr. Eugene Kroon MD is appointed CEO of EACL.
EA brings over two decades of clinical research experience in Ph I-IV trials, PK/PD services, clinical trial laboratory, and clinical data management on a global scale. EA has centers in oncology at Berlin, in diagnostic imaging agents in Frankfurt, and in stem cell therapy and diabetes at Bangalore. Chula CRC brings experience in PK/PD, clinical trial laboratory, data management, and HIV research in Thailand and SEA region.
Speaking on the joint venture, Dr. Kiat Ruxrungtham, Professor of Medicine, Chulalongkorn University and Chairman of EACL said, “We look forward to further expanding our model of hands-on local study and investigator relationship management in Southeast Asia for our clients through the joint venture with EA.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.